These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25035121)

  • 1. Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial.
    Ahmed AI; van den Elsen GA; Colbers A; van der Marck MA; Burger DM; Feuth TB; Rikkert MG; Kramers C
    Eur Neuropsychopharmacol; 2014 Sep; 24(9):1475-82. PubMed ID: 25035121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
    Klumpers LE; Beumer TL; van Hasselt JG; Lipplaa A; Karger LB; Kleinloog HD; Freijer JI; de Kam ML; van Gerven JM
    Br J Clin Pharmacol; 2012 Jul; 74(1):42-53. PubMed ID: 22680341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study.
    de Vries M; van Rijckevorsel DCM; Vissers KCP; Wilder-Smith OHG; van Goor H;
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1079-1086.e4. PubMed ID: 27720917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.
    de Vries M; Van Rijckevorsel DC; Vissers KC; Wilder-Smith OH; Van Goor H
    Br J Clin Pharmacol; 2016 Mar; 81(3):525-37. PubMed ID: 26505163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
    Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
    Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia.
    Ahmed AI; van den Elsen GA; Colbers A; Kramers C; Burger DM; van der Marck MA; Olde Rikkert MG
    Psychopharmacology (Berl); 2015 Jul; 232(14):2587-95. PubMed ID: 25752889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration.
    Gustafson RA; Kim I; Stout PR; Klette KL; George MP; Moolchan ET; Levine B; Huestis MA
    J Anal Toxicol; 2004 Apr; 28(3):160-7. PubMed ID: 15107145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial.
    Almog S; Aharon-Peretz J; Vulfsons S; Ogintz M; Abalia H; Lupo T; Hayon Y; Eisenberg E
    Eur J Pain; 2020 Sep; 24(8):1505-1516. PubMed ID: 32445190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy.
    Narang S; Gibson D; Wasan AD; Ross EL; Michna E; Nedeljkovic SS; Jamison RN
    J Pain; 2008 Mar; 9(3):254-64. PubMed ID: 18088560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.
    Stott CG; White L; Wright S; Wilbraham D; Guy GW
    Eur J Clin Pharmacol; 2013 Apr; 69(4):825-34. PubMed ID: 23052407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers.
    Schindler EAD; Schnakenberg Martin AM; Sewell RA; Ranganathan M; DeForest A; Pittman BP; Perrino A; D'Souza DC
    Psychopharmacology (Berl); 2020 Oct; 237(10):3097-3107. PubMed ID: 32632491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model.
    Hunault CC; van Eijkeren JC; Mensinga TT; de Vries I; Leenders ME; Meulenbelt J
    Toxicol Appl Pharmacol; 2010 Aug; 246(3):148-53. PubMed ID: 20450927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.
    Karst M; Salim K; Burstein S; Conrad I; Hoy L; Schneider U
    JAMA; 2003 Oct; 290(13):1757-62. PubMed ID: 14519710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between naltrexone and oral THC in heavy marijuana smokers.
    Haney M; Bisaga A; Foltin RW
    Psychopharmacology (Berl); 2003 Feb; 166(1):77-85. PubMed ID: 12491025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.
    Englund A; Atakan Z; Kralj A; Tunstall N; Murray R; Morrison P
    J Psychopharmacol; 2016 Feb; 30(2):140-51. PubMed ID: 26577065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans.
    Naef M; Russmann S; Petersen-Felix S; Brenneisen R
    J Pharm Sci; 2004 May; 93(5):1176-84. PubMed ID: 15067694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Secondary Analysis from a Randomized Trial on the Effect of Plasma Tetrahydrocannabinol Levels on Pain Reduction in Painful Diabetic Peripheral Neuropathy.
    Wallace MS; Marcotte TD; Atkinson JH; Padovano HT; Bonn-Miller M
    J Pain; 2020; 21(11-12):1175-1186. PubMed ID: 32565122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.